Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04103489 · ClinicalTrials.gov registry record · Phase 1
The Use of Eculizumab in HELLP Syndrome
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04103489: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT04103489 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04103489, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This research study is being performed to see if women diagnosed with early preterm Hemolysis, Elevated Liver Enzymes, Low Platelets (HELLP) syndrome (estimated gestational ages of 23-30 weeks) benefit from a medication called eculizumab (ECU). This drug blocks a part of the immune system called complement. By blocking this part of the immune system, eculizumab may stop or reverse the progression of the HELLP syndrome disease. The investigators will also look to see if this drug is effective and benefits both the mother and fetus.
Interventions
- DRUG Eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2023-09-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04103489
The ClinicalTrials.gov registry entry for NCT04103489 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eculizumab is the first listed.
NCT04103489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04103489 about?
NCT04103489 is a clinical study titled "The Use of Eculizumab in HELLP Syndrome". This research study is being performed to see if women diagnosed with early preterm Hemolysis, Elevated Liver Enzymes, Low Platelets (HELLP) syndrome (estimated gestational ages of 23-30 weeks) benefit from a medication called eculizumab (ECU). This drug blocks a part of the immune system called com...
What is the current status of trial NCT04103489?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-02-23. Estimated completion is 2023-09-04.
What interventions are being tested in trial NCT04103489?
The interventions under investigation include: Eculizumab (DRUG).
Who is sponsoring clinical trial NCT04103489?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.